Mirren

Johannesburg, South Africa Founded: 1983 • Age: 43 yrs Acquired By Cipla
Natural gas assets are developed alongside innovative pipeline solutions.

About Mirren

Mirren is a Healthcare company based in Johannesburg (South Africa) founded in 1983, and was acquired by Cipla in July 2018. Natural gas assets are developed alongside innovative pipeline solutions. The company has 2,319 employees. Its chief executive, as recorded, is Andrew King. Its Indian entity Cipla Limited reported revenue of β‚Ή20,103 Cr. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Mirren was founded in 1983 in Johannesburg, South Africa, within the energy sector. Natural gas resources are explored and developed using an agile approach, encompassing both conventional and coal seam gas extraction. Virtual pipeline solutions are implemented for efficient transportation to infrastructure or end-users. Participation occurs in carbon capture and sequestration initiatives to support sustainability. Operations are centered in South Africa.

  • Headquarters Johannesburg, South Africa
  • Employees 2,319
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website mirren.co.za
  • Social LinkedIn X Facebook Instagram YouTube
  • Acquired by Cipla (Jul 2018)
  • Legal Name Cipla Ltd.
  • Date of Incorporation 17 Aug, 1935
  • Jurisdiction Mumbai, Maharashtra, India
Key Metrics
  • Indian entity revenue
    ₹20,103 Cr

    FY 2026 · +5% YoY

  • Indian entity net profit
    ₹3,806 Cr

    FY 2026 · 10% margin

  • Indian entity EBITDA
    ₹5,607 Cr

    FY 2026 · 14% margin

  • Investors
  • Employee Count
    2,319
  • Acquired by
    Cipla

    (Jul 2018)

Apps and channels of Mirren

its YouTube channel Cipla Africa has 1.08K subscribers and 30 videos.

Cipla Africa
YouTube 1.08K subscribers 30 videos Howto & Style
Open channel

Videos from Mirren

The most watched videos on Mirren's YouTube channel, Cipla Africa (1.08K subscribers). Click a video to play it here.

Cipla Out of the mouths of the babes: Gout
58.6K views
Out of the Mouth: Sexual Health
52.4K views
Cipla Out of the mouths of the babes: Fever
49.6K views
Cipla Out of the mouths of the babes: Inflammation
37.3K views

More on Cipla Africa.

Investors in Mirren

Mirren has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cipla.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
APIs, generic drugs, and formulation services are manufactured.
1935cipla.comMumbai, India
Premium access

Investor details for Mirren

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Cipla Limited (Mirren)

Cipla Limited is the primary company behind Mirren. The board of Cipla Limited currently have 10 directors; the longest-serving is Yusuf Khwaja Hamied, appointed in 1972. 32 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Yusuf Khwaja Hamied
DIN 00029049
Director21 Jul 197254 yrs 3 moCipla Limited
Adil Zainulbhai
DIN 06646490
Director23 Jul 201412 yrs 3 moCipla Limited
Prathivadibhayankara Rajagopalan Ramesh
DIN 01915274
Director01 Jul 20215 yrs 4 moCipla Limited
Mandar Purushottam Vaidya
DIN 09690327
Director29 Jul 20224 yrs 3 moCipla Limited
Balram Bhargava
DIN 10479707
Director01 Apr 20242 yrs 7 moCipla Limited
Sharmila Nitin Paranjpe
DIN 02328770
Director01 Sep 20242 yrs 2 moCipla Limited
Abhijit Jagdish Joshi
DIN 07115673
Director03 Sep 20242 yrs 2 moCipla Limited
Kamil Hamied
DIN 00024292
Director01 Nov 20242 yrsCipla Limited
Maya Hari
DIN 01123969
Director01 Nov 20242 yrsCipla Limited
Achin Gupta
DIN 09491674
Managing Director01 Apr 20267 moCipla Limited

People of Mirren

1 people are tracked at Mirren (1 in leadership); the tracked headcount is 2,319.

NameRoleGroup
Andrew King
CEOLeadership
Premium access

Complete people profiles for Mirren

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Mirren

Figures of Cipla Limited, the primary company behind Mirren, for FY 2026. Revenue was ₹20,103 Cr (+5% year on year). Net profit was ₹3,806 Cr (10% margin). EBITDA was ₹5,607 Cr (14% margin). Revenue has grown at a compounded annual rate of +8% over three years and +7% over five years.

  • ₹20,103 CrRevenue · FY 2026 · +5% YoY
  • ₹3,806 CrNet profit · 10% margin
  • ₹5,607 CrEBITDA · 14% margin
  • ₹162 CrPaid-up capital
  • 25,952Employees (provident fund records)
  • +8%Revenue CAGR, 3 years
  • +7%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Cipla Limited are on its company page.

Premium access

Detailed financial statements for Mirren

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Mirren

2 dated milestones of Mirren across 35 years, from founding to its latest funding, stage changes and deals.

  1. Founded Mirren is founded.
  2. Exit Acquired by Cipla.

Web traffic of Mirren

Websites that share an audience with Mirren (mirren.co.za).

Similar websites

Websites whose visitors overlap most with Mirren. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
pumc-pharm.com
pumc-pharm.com
100%
–
1bp.com.cn
1bp.com.cn
80%
–
pankajakasthuri.in
55%
31.4K#580,161View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Mirren

Cipla: HSBC on Cipla Maintains Hold, Target Price Rs 1,400; Q2 performance was lacklustre, with FY27 EBITDA margin guidance of 18.5–20% and the US$1bn annualised US-sales exit-rate target unchanged. Execution of key US launches, particularly inhalers, remains critical to meeting guidance.
Exchange Update β€’ 12 days ago
Cipla: CLSA on Cipla Maintains Outperform, Target Price Rs 1,600; Q2 revenue marginally missed estimates despite record India performance led by Yurpeak, while margins improved QoQ on a better product mix. Cipla reiterated its US$1bn FY27 US-sales exit-rate target, supported by three new launches and growth in generic Ventolin and Advair; it plans to file 45–50 complex products over three years.
Exchange Update β€’ 12 days ago
CIPLA: Q2 CONS NET PROFIT 8.8B RUPEES VS 13.5B (YOY); EST 9.5B
Exchange Update β€’ 13 days ago
CIPLA: Q2 REVENUE 74B RUPEES VS 75.9B (YOY); EST 74.98B
Exchange Update β€’ 13 days ago
CIPLA: Q2 EBITDA 13.87B RUPEES VS 18.94B (YOY), EST 13.71B; Q2 EBITDA MARGIN 18.74% VS 24.97% (YOY), EST 18.3%
Exchange Update β€’ 13 days ago
Cipla: Co's Focus On Growth In North America Through New Product Launches
Exchange Update β€’ 13 days ago
Cipla: Co Plans To Reach $1 Billion Revenue In North America By FY27
Exchange Update β€’ 13 days ago
Cipla: Co Maintain 18.5 - 20% EBITDA Margin Guidance For FY27
Exchange Update β€’ 13 days ago
Cipla: Respiratory Drug Ventolin To Contribute Growth In U.S In Coming Quarters
Exchange Update β€’ 13 days ago
Maharashtra FDA Cancels Cipla Unit’s Drug Sale Licence Over Alleged Violations - Newspaper
Exchange Update β€’ 1 month ago
Premium access

Complete news archive for Mirren

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mirren

Mirren was founded in 1983.

Mirren is headquartered in Johannesburg, South Africa. It is registered at Johannesburg, Gauteng, South Africa.

Andrew King is the CEO of Mirren, as recorded in our data.

Mirren has 2,319 employees.

The primary company behind Mirren, Cipla Limited, reported revenue of β‚Ή20,103 Cr for FY 2026, up 5% year on year.

Mirren was founded in 1983 in Johannesburg, South Africa, within the energy sector. Natural gas resources are explored and developed using an agile approach, encompassing both conventional and coal seam gas extraction. Virtual pipeline solutions are implemented for efficient transportation to infrastructure or end-users. Participation occurs in carbon capture and sequestration initiatives to support sustainability. Operations are centered in South Africa.

Mirren has 1 investor. Key investors include Cipla.

Mirren operates through Cipla Limited.

Yes. Mirren was acquired by Cipla in July 2018.

The legal entities of Mirren currently have 12 directors, including Prathivadibhayankara Rajagopalan Ramesh, Mandar Purushottam Vaidya, Yusuf Khwaja Hamied and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available